biostudies-literatureVaubel RAHHS | National Institutes of HealthAlpha Omega Alpha Carolyn L. Kuckein Student Research FellowshipNHLBI NIH HHSMayo ClinicNCI NIH HHSNINDS NIH HHSAccelerate Brain Cancer Cure1094-1104https://www.ebi.ac.uk/biostudies/studies/S-EPMC7056576biostudies-literatureUnknown26(5)<h4>Purpose</h4>Glioblastoma is the most frequent and lethal primary brain tumor. Development of novel therapies relies on the availability of relevant preclinical models. We have established a panel of 96 glioblastoma patient-derived xenografts (PDX) and undertaken its genomic and phenotypic characterization.<h4>Experimental design</h4>PDXs were established from glioblastoma, IDH-wildtype (<i>n</i> = 93), glioblastoma, IDH-mutant (<i>n</i> = 2), diffuse midline glioma, H3 K27M-mutant (<i>n</i> = 1), and both primary (<i>n</i> = 60) and recurrent (<i>n</i> = 34) tumors. Tumor growth rates, histopathology, and treatment response were characterized. Integrated molecular profiling was performed by whole-exome sequencing (WES, <i>n</i> = 83), RNA-sequencing (<i>n</i> = 68), and genome-wide metClinical cancer research : an official journal of the American Association for Cancer ResearchGenomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.PMC7056576P50 CA108961R24 NS092940U01 CA227954R35 CA197745R01 CA230712P30 CA015083U01 CA217858RO1 CA184320R01 CA184320R25 HL092621Peng SCarlson BLDhruv HDKitange GJKollmeyer TMRemonde DMladek ACEvers LMarin BMGrove RWang QGiannini CMa DJJenkins RBSulman EPBerens MEMeyer FBSarkar GVerhaak RGSchroeder MAParney IFO'Neill BPKlee EWTran NLEckel-Passow JEVaubel RACalifano ALaChance DHCaron ATian SBurns TCDecker PAYan HSarkaria JNfalseGenomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.<h4>Purpose</h4>Glioblastoma is the most frequent and lethal primary brain tumor. Development of novel therapies relies on the availability of relevant preclinical models. We have established a panel of 96 glioblastoma patient-derived xenografts (PDX) and undertaken its genomic and phenotypic characterization.<h4>Experimental design</h4>PDXs were established from glioblastoma, IDH-wildtype (<i>n</i> = 93), glioblastoma, IDH-mutant (<i>n</i> = 2), diffuse midline glioma, H3 K27M-mutant (<i>n</i> = 1), and both primary (<i>n</i> = 60) and recurrent (<i>n</i> = 34) tumors. Tumor growth rates, histopathology, and treatment response were characterized. Integrated molecular profiling was performed by whole-exome sequencing (WES, <i>n</i> = 83), RNA-sequencing (<i>n</i> = 68), and genome-wide met2020-01-01T00:00:00Z2020 Mar2026-05-04T19:59:39.135Z2020-09-05T07:14:38ZS-EPMC70565763185283110.1158/1078-0432.CCR-19-090910.1158/1078-0432.ccr-19-0909